Navigation Links
USC researchers find new clues about protein linked to Parkinson's disease
Date:6/17/2011

Researchers at the Keck School of Medicine of the University of Southern California (USC) have uncovered structural clues about the protein linked to Parkinson's disease (PD), which ultimately could lead to finding a cure for the degenerative neurological disorder.

The alpha-synuclein (α-synuclein) protein is commonly found in the healthy human brain even though its function is not clear. The protein has been the subject of substantial Parkinson's research, however, because it is a major component in the protein clumps found in PD cases.

Unlike most proteins, which are typically rigid and occur in one definitive form, the alpha-synuclein protein can fold and change its structure. Researchers Tobias S. Ulmer, Ph.D. and Sowmya Bekshe Lokappa, Ph.D. at the Keck School-affiliated Zilkha Neurogenetic Institute have determined that the energy difference between two particular alpha-synuclein structures is less than previously speculated.

Their study, to be published in the June 17 issue of The Journal of Biological Chemistry, is the first to quantify that energy difference, 1.20.4 kcal/mol.

"We're trying to understand the mechanisms of protein folding and misfolding," said Ulmer, the study's principal investigator and an assistant professor in the Department of Biochemistry and Molecular Biology at the Zilkha Neurogenetic Institute. "Then we can say why something is going wrong, which is essential to treating neurodegenerative disorders like Parkinson's."

If proteins misfold, they are repaired or they break down. However, when alpha-synuclein misfolds it aggregates and becomes toxic to surrounding nerve cells, Ulmer said. Understanding its folding and finding what causes aberrant folding is therefore key to determining the root cause of the disorder, he added.

To put the discovery into perspective, Ulmer compared the energy that researchers thought was needed to change the protein's structure to hurricane-force winds and the actual energy required to a light summer breeze. The experiments were conducted in 2010, measuring the energy of elongated and broken helix forms of alpha-synuclein through circular dichroism spectroscopy, fluorescence spectroscopy and isothermal titration calorimetry.

"There may be a continuous interconversion between folded alpha-synuclein structural states that might contribute to its pathological misfolding," said Lokappa, a post-doctoral research associate at the Center for Craniofacial Molecular Biology at USC and the study's co-author. "But we need to have even better insight into the mechanisms of protein folding and misfolding to explain what's going wrong in the brain."

The paper is the sixth in a series of studies that Ulmer has published on alpha-synuclein.

Parkinson's is a neurological disorder that has no cure or determined cause. It is a slow-progressing degenerative disease that most commonly affects motor function. According to the National Parkinson Foundation, the disorder is the second-most common neurodegenerative disease after Alzheimer's, affecting 1 million people in the United States and some 4 million worldwide.


'/>"/>

Contact: Alison Trinidad
alison.trinidad@usc.edu
323-442-3941
University of Southern California
Source:Eurekalert

Related biology news :

1. GW researchers receive award from NCI to study cancer from a neglected tropical disease
2. MSU plant scientist named one of the nations most innovative researchers
3. Leaky genes put evolution on the fast track, Pitt and UW-Madison researchers find
4. Researchers predict record Gulf of Mexico dead zone due to Mississippi River flooding
5. Researchers identify why dopamine replacement therapy has a paradoxical effect on cognition
6. Researchers improve method for finding genetic mistakes that fuel cancer
7. Johns Hopkins researchers link cell division and oxygen levels
8. U-M researchers find potential new way to fight sepsis
9. Penn researchers show new evidence of genetic arms race against malaria
10. Penn researchers develop biological circuit components, new microscope technique for measuring them
11. Researchers discover potential cause of chronic painful skin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2017)... Summary This report provides all the information you ... activities since 2010. ... Read the full report: http://www.reportlinker.com/p03605615-summary/view-report.html ... an in-depth insight into the partnering activity of one of ... company reports are prepared upon purchase to ensure inclusion of ...
(Date:3/2/2017)... Australian stem cell and regenerative medicine company, ... an agreement with the Monash Lung Biology Network, a ... and Department of Pharmacology at Monash University, ... to support the use of Cymerus™ mesenchymal stem cells ... Asthma is a chronic, long term lung condition recognised ...
(Date:2/28/2017)... -- News solutions for biometrics, bag drop and New ... At ... 16 March, Materna will present its complete end-to-end passenger journey, ... a real benefit for passengers. To accelerate the whole passenger ... point solutions to take passengers through the complete integrated process ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... March 23, 2017  Northwest Biotherapeutics (OTCQB: NWBO) ... immune therapies for solid tumor cancers, today announced ... financing it announced last Friday, March 17, 2017. ... institutional investors securities totaling 28,843,692 shares, comprised of ... 10,000,000 shares of Class C Warrants pre-funded at ...
(Date:3/23/2017)...  BioPharmX Corporation (NYSE MKT: BPMX), a specialty ... today reported financial results for the quarter and ... an update on the company,s clinical development efforts ... are pleased to report that last year was ... Anja Krammer. "We achieved key clinical milestones and ...
(Date:3/23/2017)... NetworkNewsWire Editorial Coverage  ... Cancer remains one of ... health care systems, in terms of costs and resources. However, ... the development of innovative and efficient therapies that demonstrate higher ... types of cancer treatments, a growing number of patients receiving ...
(Date:3/23/2017)... , March 23, 2017 ... at four equities in the Biotech industry: Sangamo Therapeutics ... Biologics Inc. (NYSE MKT: SYN), and Regulus Therapeutics Inc. ... st , 2017, Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology ... downloading their free report at: ...
Breaking Biology Technology: